Current Issue - March 2024, Volume 18, Issue No. 1

1. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general Diabetes Metab Res Rev. 2000; 16(3): 164-71. doi: 10.1002/1520-7560(200005/06)16:3<164::aid-dmrr103>3.0.co;2-r
2. Ganesan K, Goyal A, Roane D. Bisphosphonate. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK470248
3. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998; 19(1): 80-100. doi: 10.1210/edrv.19.1.0325
4. Siris ES. Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res. 1994; 9(3): 303-4. doi: 10.1002/jbmr.5650090302
5. Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 2001; 44(11): 2032-7. doi: 10.1007/s001250100008
6. Moreno M, Gratacós J, Casado E, Galisteo C, Orellana C, Larrosa M. Utilidad del pamidronato en el tratamiento de la artropatía de Charcot [Usefulness of Pamidronate in the Treatment of Charcot's Arthropathy]. Reumatol Clin. 2007; 3(6): 257-61. Spanish. doi: 10.1016/S1699-258X(07)73700-2
7. Naqvi A, Cuchacovich R, Saketkoo L, Espinoza LR. Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up. Am J Med Sci. 2008; 335(2): 145-8. doi: 10.1097/MAJ.0b013e3180a5e957
8. Bharath R, Bal A, Sundaram S, Unnikrishnan AG, Praveen VP, Bhavani N, et al. A comparative study of zoledronic acid and once weekly Alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus. Indian J Endocrinol Metab. 2013; 17(1): 110-6. doi: 10.4103/2230-8210.107818
9. Armstrong DG, Todd WF, Lavery LA, Harkless LB, Bushman TR. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med. 1997; 14(5): 357-63. doi: 10.1002/(SICI)1096-9136(199705)14:5<357::AID-DIA341>3.0.CO;2-8
10. Game FL, Catlow R, Jones GR, Edmonds ME, Jude EB, Rayman G, et al. Audit of acute Charcot's disease in the UK: the CDUK study. Diabetologia. 2012; 55(1): 32-5. doi: 10.1007/s00125-011-2354-7
11. Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM. Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg. 2004; 43(5): 285-9. doi: 10.1053/j.jfas.2004.07.005
12. Greco T, Mascio A, Comisi C, Polichetti C, Caravelli S, Mosca M, et al. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. Int J Mol Sci. 2023; 24(3): 3014. doi: 10.3390/ijms24033014
13. Rastogi A, Bhansali A, Jude EB. Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2021; 58(6): 687-96. doi: 10.1007/s00592-020-01664-9

Abstract   |   Reference